בהודעה מטעם חברת אוונטיס נמסר כי בכנס ADA המתקיים השבוע תציג החברה נתוני מחקרים חדשים שנעשו בלנטוס ואפידרה.

ע”פ המימצאים שהחברה מציגה בכנס, לנטוס בשילוב עם תרופה פומית אנטיסוכרתית מפחיתה אירועי היפוגליקמיה בהשוואה לטיפול ב-NPH . האינסולין החדש לטווח קצר, האפידרה,  השיג ירידה משמעותית ברמות הסוכר בזמן הארוחות.

להלן הידיעה המלאה של החברה כפי שהועברה אלינו:

Aventis Highlights Clinical Trials of Lantus® and Apidra” at the American Diabetes Association Annual Meeting

Aventis Press Release

Strasbourg, France, June 7, 2004 Recent estimates by the World Health Organization (WHO) calculate at least 171 million people worldwide suffer from diabetes and expect this figure to more than double, to reach 366 million, by 2030.  In this context, Aventis will present new data on its key insulin products, including Lantus (insulin glargine [rDNA origin] injection) and the newly FDA approved Apidra (insulin glulisine [rDNA origin] injection) at the American Diabetes Association (ADA) 64th Annual Scientific Sessions.  These findings demonstrate how Lantus and Apidra can help people with diabetes and their physicians safely manage their disease.

Here is a brief highlight of the data:

24-Hour Lantus Helps Patients Achieve Glycemic Control in Real-life Study of Type 2 Diabetes
In an observational study of more than 12,000 patients treated in clinical practice, Lantus in combination with oral therapy is effective in lowering blood glucose levels in patients who had been inadequately controlled on oral therapy alone. Lantus plus oral antidiabetic medications allows patients to achieve blood glucose (sugar) control.

Another study at this year’s ADA meeting demonstrated the benefits of Lantus therapy on blood glucose control. The retrospective study compared the differences in medically recorded hypoglycemic event rates of patients newly initiated on Lantus or NPH (Neutral Protamine Hagedorn) showed that patients who started Lantus therapy had fewer episodes of hypoglycemia (low blood sugar) at a given A1C level than those who had begun taking intermediate-acting NPH insulin.

Apidra Offers Safe and Effective Glucose Control When Injected Before or After Meals

Apidra (insulin glulisine [rDNA origin] injection), a new rapid-acting insulin analog, can safely and effectively lower blood glucose (sugar) levels when used either within 15 minutes before or within 20 minutes after starting a meal in people with type 1 diabetes.  Both dosing regimens lowered levels of A1Ca key measure of blood glucose controlcomparable to an injection of regular human insulin given 30-45 minutes before mealtime.  Apidra can be administered pre or post meal allowing for flexibility and timing of injection when a prandial insulin is needed.

Apidra Shows Statistically Significant Improvement in Mealtime Glycemic Control in Type 2 Diabetes

Apidra achieved statistically significant control of blood glucose (sugar) in people with type 2 diabetes.  In a large, randomized study, Apidra plus a basal  insulin offered safe and effective lowering of blood glucose, with no increased risk of hypoglycemia (low blood sugar) or weight gain.